- CORPORATE OVERVIEW
- INVESTMENT APPROACH
- GIPS COMPOSITES
- FUNDS - LUXEMBOURG
The investment objective of the C WorldWide Biotechnology fund is to achieve long-term capital growth by investing globally in a limited number of biotechnology companies. Investments are made in small and medium-sized fast-growing and research-intensive companies.
Our management team has a close collaboration with a scientific advisory board made up of leading scientists at the Karolinska Institute. This gives us unique insight into the forefront of medical research and valuable knowledge for example in evaluating the commercial potential of research projects.
Our investment decisions are based on thorough, fundamental equity research. This analysis is combined with dialogue with scientists as mentioned above and creates opportunities to put together a concentrated portfolio of 25-50 companies which we have detailed knowledge of, and which in our opinion constitute the most interesting investment opportunities in the long term.